EU/3/09/685 - orphan designation for treatment of pancreatic cancer

N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride
OrphanHuman

Overview

On 9 November 2009, orphan designation (EU/3/09/685) was granted by the European Commission to Merck KGaA, Germany, for N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride for the treatment of pancreatic cancer.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 2 September 2009 recommending the granting of this designation.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in July 2020 on request of the Sponsor.

Pancreatic cancer is cancer of the pancreas, a small organ that lies behind the stomach. The pancreas has two functions: producing a juice that helps with the digestion of food, and producing hormones such as insulin. Due to the absence of symptoms in the early stages of the disease, the majority of patients are diagnosed when the cancer has spread locally or to other parts of the body.
Pancreatic cancer is a very severe and life-threatening disease that leads to poor long-term survival.

At the time of designation, pancreatic cancer affected approximately 1.3 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 66,000 people, and is below the threshold for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and knowledge of the Committee for Orphan Medicinal Products (COMP).

At the time of submission of the application for orphan drug designation, several medicines were authorised for pancreatic cancer in the EU. The choice of treatment for pancreatic cancer depended on several factors, including how advanced the disease is. Treatments included surgery, radiotherapy (treatment with radiation) and chemotherapy (medicines to treat cancer).
The sponsor has provided sufficient information to show that this medicine might be of significant benefit for patients with pancreatic cancer because early studies in experimental models indicate that it might improve the treatment of this condition when used in combination with existing treatments. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride is expected to work by blocking an enzyme called MEK1/2, which is involved in stimulating cells to grow and divide. MEK1/2 is over-activated in cancer cells, which makes these cells divide uncontrollably. By blocking this enzyme, the medicine is expected to control cell division and slow down the rate of growth of the cancer.

The effects of N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride have been evaluated in experimental models.
At the time of submission of the application for orphan designation, no clinical trials with the designated product in patients with pancreatic cancer had been started.
At the time of submission, this medicine was not authorised anywhere in the EU for pancreatic cancer or designated as orphan medicinal product elsewhere for this condition.

  • the seriousness of the condition;
  • the existence of alternative methods of diagnosis, prevention or treatment;
  • either the rarity of the condition (affecting not more than 5 in 10,000 people in the Community) or insufficient returns on investment

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/09/685: Public summary of positive opinion for orphan designation ofN-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride for the treatment of pancreatic cancer

Adopted Reference Number: EMEA/COMP/577406/2009

English (EN) (324.25 KB - PDF)

First published: Last updated:
View

Key facts

Active substance
N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride
Intended use
Treatment of pancreatic cancer
Orphan designation status
Withdrawn
EU designation number
EU/3/09/685
Date of designation
Sponsor

Merck KGaA
Frankfurter Strasse 250
D-64293 Darmstadt
Germany
Telephone: +49 61 51 72 0
Telefax: +49 61 51 72 20 00
E-mail: service@merck.de

EMA list of opinions on orphan medicinal product designation

EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Share this page